Loading clinical trials...
Loading clinical trials...
A Randomized, 2-arm Non-comparative Phase II Study on the Efficacy of Atezolizumab and Roche Bevacizumab (Atezo/Bev) Followed by On-demand Selective TACE (sdTACE) Upon Detection of Disease Progression or of Initial Synchronous Treatment With TACE and Atezo/Bev on 24-months Survival Rate in the Treatment of Unresectable Hepatocellular Carcinoma Patients
Conditions
Interventions
Atezolizumab Injection, Bevacizumab Injection
Locations
7
Germany
University of Bonn
Bonn, Germany
University Hospital Cologne
Cologne, Germany
Hospital of the University of Munich
Munich, Germany
Klinikum Rechts der Isar of the Technical University Munich
Munich, Germany
University Hospital Regensburg
Regensburg, Germany
University Hospital Tübingen
Tübingen, Germany
Start Date
June 10, 2020
Primary Completion Date
March 1, 2025
Completion Date
March 1, 2025
Last Updated
June 14, 2024
NCT06707233
NCT05911633
NCT06187961
NCT06561399
NCT06397222
NCT05901194
Lead Sponsor
Ludwig-Maximilians - University of Munich
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions